Volume 10, Issue 1, Supplement 1 January 2014
The 64th Annual Meeting of the American Association for the Study of Liver Diseases
November 1-5, 2013 • Washington DC
Special Reporting on:
- Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection
- Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection
- Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations
- All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV
- Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in Difficult-to-Treat HCV Infection
- Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNA
PLUS Meeting Abstract Summaries
With Expert Commentary by:
Ira M. Jacobson, MD
Weill Cornell Medical College New York, New York